WCG Wealth Advisors LLC Raises Position in IQVIA Holdings Inc. $IQV

WCG Wealth Advisors LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 103.1% during the 4th quarter, HoldingsChannel reports. The fund owned 33,582 shares of the medical research company’s stock after acquiring an additional 17,047 shares during the quarter. WCG Wealth Advisors LLC’s holdings in IQVIA were worth $7,570,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IQV. Boston Partners acquired a new position in shares of IQVIA in the third quarter worth about $676,698,000. Norges Bank acquired a new position in shares of IQVIA in the fourth quarter worth about $497,445,000. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares in the last quarter. Citigroup Inc. lifted its stake in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after acquiring an additional 475,557 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.8%

NYSE:IQV opened at $182.12 on Thursday. IQVIA Holdings Inc. has a 52 week low of $143.00 and a 52 week high of $247.04. The firm has a market capitalization of $30.40 billion, a PE ratio of 22.57, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21. The stock has a 50 day moving average of $171.35 and a 200-day moving average of $195.26. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.58 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. UBS Group cut their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, April 19th. Finally, Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.